CRBP Short Information, Corbus Pharmaceuticals Holdings Inc.

Twenty Trading Day Totals
Total Shorted Volume	3,186,691
Total Actual Volume	13,007,533

Averages
Average Short Volume	159,335
Average Short Percentage	44.63%

Is there a CRBP Short Squeeze or Breakout about to happen?

See the CRBP Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2022-06-30	0.257	0.2522	0.2697	0.25	404,113	110,513	50.5917
2022-06-29	0.2753	0.253	0.28	0.25	812,679	245,021	59.9122
2022-06-28	0.27	0.2697	0.2895	0.2633	503,747	86,218	42.9311
2022-06-27	0.2732	0.2669	0.2867	0.2633	763,190	125,300	29.3800
2022-06-24	0.2957	0.2518	0.3082	0.2503	962,906	106,196	31.5368
2022-06-23	0.2886	0.2823	0.292	0.2705	529,453	133,302	39.3465
2022-06-22	0.29	0.2755	0.2925	0.2705	330,148	56,524	41.4438
2022-06-21	0.285	0.2874	0.3	0.2661	543,517	108,642	29.1985
2022-06-16	0.2565	0.233	0.2691	0.2219	928,803	205,989	45.2456
2022-06-15	0.253	0.263	0.27	0.253	584,496	134,444	48.7602
2022-06-14	0.2731	0.2529	0.2799	0.2528	473,548	149,522	55.2551
2022-06-13	0.29	0.2601	0.2901	0.26	614,141	150,839	46.0470
2022-06-09	0.2935	0.298	0.3165	0.2815	727,215	166,518	45.4057
2022-06-08	0.2813	0.293	0.3	0.2813	425,378	107,294	48.0202
2022-06-06	0.3092	0.2973	0.31	0.28	247,542	27,039	32.0922
2022-06-03	0.294	0.3042	0.3124	0.29	428,172	139,069	47.3236
2022-06-02	0.2978	0.2938	0.3037	0.2853	373,664	59,234	41.7009
2022-06-01	0.3	0.2999	0.32	0.2717	1,675,312	632,837	54.8871
2022-05-31	0.3	0.3034	0.3099	0.285	1,214,427	338,085	58.1671
2022-05-27	0.3038	0.2962	0.3038	0.2903	465,082	104,105	45.4272

Stock Information

Corbus Pharmaceuticals Holdings Inc. Company Name:

CRBP Stock Symbol:

NASDAQ Market:

Get CRBP Alerts

News, Short Squeeze, Breakout and More Instantly...

CRBP - Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference

Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference PR Newswire CRB-601 is a highly potent and selective anti -αvβ8 integrin monoclonal antibody designed to block t...
CRBP - Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Promising pre-clinical data generated for CRB-601 across several tumor models as monotherapy and in combination with anti-PD1 therapy IND submission ...
CRBP - Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting

Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting PR Newswire NORWOOD, Mass. , April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Comp...